Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey

被引:13
|
作者
Voko, Zoltan [1 ,2 ]
Cheung, Kei Long [3 ]
Jozwiak-Hagymasy, Judit [2 ]
Wolfenstetter, Silke [4 ]
Jones, Teresa [5 ]
Munoz, Celia [6 ]
Evers, Silvia M. A. A. [3 ]
Hiligsmann, Mickael [3 ]
de Vries, Hein [7 ]
Pokhrel, Subhash [5 ]
机构
[1] Eotvos Lorand Univ, Fac Social Sci, Dept Hlth Policy & Hlth Econ, Pazmany Peter Setany 1-A, H-1117 Budapest, Hungary
[2] Syreon Res Inst, Mexikoi Ut 65-A, H-1142 Budapest, Hungary
[3] Maastricht Univ, Caphri Sch Publ Hlth & Primary Care, Hlth Serv Res, Duboisdomein 30, NL-6229 GT Maastricht, Netherlands
[4] Helmholtz Zentrum Munchen, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[5] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England
[6] Pompeu Fabra Univ, Ctr Res Hlth & Econ, Ramon Trias Fargas 25-27, Barcelona 08005, Spain
[7] Maastricht Univ, Hlth Promot, Caphri Sch Publ Hlth & Primary Care, POB 6166, NL-6200 MD Maastricht, Netherlands
来源
关键词
Smoking cessation; EQUIPT; Stakeholder engagement; Return on investment; Transferability of economic evidence; ECONOMIC EVALUATIONS; COST-EFFECTIVENESS; TRANSFERABILITY; CRITERIA; MAKERS; POLICY;
D O I
10.1186/s12961-016-0110-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) project aimed to study transferability of economic evidence by co-creating the Tobacco Return On Investment (ROI) tool, previously developed in the United Kingdom, for four sample countries (Germany, Hungary, Spain and the Netherlands). The EQUIPT tool provides policymakers and stakeholders with customized information about the economic and wider returns on the investment in evidence-based tobacco control, including smoking cessation interventions. A Stakeholder Interview Survey was developed to engage with the stakeholders in early phases of the development and country adaptation of the ROI tool. The survey assessed stakeholders' information needs, awareness about underlying principles used in economic analyses, opinion about the importance, effectiveness and cost-effectiveness of tobacco control interventions, and willingness to use a Health Technology Assessment (HTA) tool such as the ROI tool. Methods: A cross sectional study using a mixed method approach was conducted among participating stakeholders in the sample countries and the United Kingdom. The individual questionnaire contained open-ended questions as well as single choice and 7- or 3-point Likert-scale questions. The results corresponding to the priority and needs assessment and to the awareness of stakeholders about underlying principles used in economic analysis are analysed by country and stakeholder categories. Results: Stakeholders considered it important that the decisions on the investments in tobacco control interventions should be supported by scientific evidence, including prevalence of smoking, cost of smoking, quality of life, mortality due to smoking, and effectiveness, cost-effectiveness and budget impact of smoking cessation interventions. The proposed ROI tool was required to provide this granularity of information. The majority of the stakeholders were aware of the general principles of economic analyses used in decision making contexts but they did not appear to have in-depth knowledge about specific technical details. Generally, stakeholders' answers showed larger variability by country than by stakeholder category. Conclusions: Stakeholders across different European countries viewed the use of HTA evidence to be an important factor in their decision-making process. Further, they considered themselves to be capable of interpreting the results from a ROI tool and were highly motivated to use it.
引用
下载
收藏
页数:17
相关论文
共 20 条
  • [1] Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey
    Zoltan Vokó
    Kei Long Cheung
    Judit Józwiak-Hagymásy
    Silke Wolfenstetter
    Teresa Jones
    Celia Muñoz
    Silvia M.A.A. Evers
    Mickaël Hiligsmann
    Hein de Vries
    Subhash Pokhrel
    Health Research Policy and Systems, 14
  • [2] REVIEW OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR RARE DISEASES ACROSS EUROPEAN COUNTRIES
    Sanchez, Garcia J. J.
    Sattar, S.
    Hill, C. A.
    VALUE IN HEALTH, 2016, 19 (07) : A491 - A491
  • [3] Automated Drugs Dispensing Systems in Hospitals: a Health Technology Assessment (HTA) Study Across Six European Countries
    Foglia, Emanuela
    Asperti, Federica
    Antonacci, Grazia
    Jani, Yogini H.
    Garagiola, Elisabetta
    Bellavia, Daniele
    Ferrario, Lucrezia
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 679 - 696
  • [4] Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
    Anna-Maria Fontrier
    Erica Visintin
    Panos Kanavos
    PharmacoEconomics - Open, 2022, 6 : 315 - 328
  • [5] Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
    Fontrier, Anna-Maria
    Visintin, Erica
    Kanavos, Panos
    PHARMACOECONOMICS-OPEN, 2022, 6 (03) : 315 - 328
  • [6] EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES
    Korge, Kristina
    Berndt, Nadine
    Hohmann, Juergen
    Romano, Florence
    Hiligsmann, Mickael
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2017, 33 (06) : 644 - 653
  • [7] The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey
    Gianluca Coppola
    Joshua D. Brown
    Amanda R. Mercadante
    Sheila Drakeley
    Nikoletta Sternbach
    Aaron Jenkins
    Karin Hygge Blakeman
    Astrid Gendolla
    BMC Public Health, 25 (1)
  • [8] Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
    Anna-Maria Fontrier
    Erica Visintin
    Panos Kanavos
    PharmacoEconomics - Open, 2022, 6 : 629 - 629
  • [9] Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
    Angelis, Aris
    Lange, Ansgar
    Kanavos, Panos
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01): : 123 - 152
  • [10] Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
    Aris Angelis
    Ansgar Lange
    Panos Kanavos
    The European Journal of Health Economics, 2018, 19 : 123 - 152